Biomarkers for personalizing omega-3 fatty acid dosing

  • Posted on: 26 March 2015
  • By: fcoldren
TitleBiomarkers for personalizing omega-3 fatty acid dosing
Publication TypeJournal Article
Year of Publication2014
AuthorsJiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, Zhao L, Uhlson CL, Hong YH, Murphy RC, Normolle DP, Smith WL, Brenner DE
JournalCancer Prev Res (Phila)
Date Published2014 Oct

Prostaglandin E2 (PGE2) has been linked to a higher risk of colorectal cancer. PGE2 in colon tissue can be reduced by increasing dietary eicosapentaenoic acid (EPA). The dose-dependent relationships between dietary EPA, serum EPA:arachidonate (AA) ratio, urinary PGE2 metabolites, and colonic eicosanoids were evaluated to develop biomarkers for prediction of colonic PGE2. Male rats were fed diets containing EPA:ω6 fatty acid ratios of 0, 0.1, 0.2, 0.4, or 0.6 for 5 weeks. Increasing the dietary EPA:ω6 fatty acid ratio increased EPA:AA ratios in serum and in the proximal, transverse, and distal colon (P < 0.001). The urinary PGE2 metabolite was reduced (P = 0.006). EPA-rich diets reduced colonic tissue PGE2 concentrations by 58% to 66% and increased PGE3 by 19- to 28-fold. Other AA-derived eicosanoids were reduced by 35% to 83%. The changes were not linear, with the largest changes in eicosanoids observed with the lower doses. A mathematical model predicts colonic tissue eicosanoids from the EPA:AA ratio in serum and the EPA dose. Every 10% increase in serum EPA:AA was associated with a 2% decrease in the (geometric) mean of PGE2 in the distal colon. These mathematical relationships can now be applied to individualized EPA dosing in clinical trials.

Alternate JournalCancer Prev Res (Phila)
PubMed ID25139294
PubMed Central IDPMC4185239
Grant ListAT002782 / AT / NCCAM NIH HHS / United States
CA130810 / CA / NCI NIH HHS / United States
GM068848 / GM / NIGMS NIH HHS / United States
HL117798 / HL / NHLBI NIH HHS / United States
M01 RR000042 / RR / NCRR NIH HHS / United States
P30 CA046592 / CA / NCI NIH HHS / United States
P50 CA130810 / CA / NCI NIH HHS / United States